Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.61 |
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | CTSC | P53634 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16468637 | 0.96 | GHSR (0.58) | GHSRACECTSC | |
| SCHEMBL9057338 | 0.91 | KDM4E (0.55) | GHSRCTSC | |
| SCHEMBL2195848 | 0.90 | GHSR (0.55) | GHSRACECTSCMMP2MMP9 | |
| SCHEMBL1650522 | 0.89 | MMP2 (0.55) | GHSRCTSCMMP2MMP9MMP8 | |
| SCHEMBL30052407 | 0.88 | ACE (0.69) | GHSRACE | |
| SCHEMBL30052433 | 0.88 | ACE (0.69) | GHSRACE | |
| SCHEMBL28752364 | 0.86 | IL1RN (0.54) | GHSRACECTSC | |
| SCHEMBL2182458 | 0.86 | IL1RN (0.54) | GHSRACECTSC | |
| SCHEMBL8397046 | 0.86 | KDM4E (0.60) | CTSC | |
| SCHEMBL8397051 | 0.86 | KDM4E (0.60) | CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261541-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170266257-A1 | METHODS OF TREATING TRAUMATIC BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266257-A1 | METHODS OF TREATING TRAUMATIC BRAIN INJURY | ATP6V1B2, FABP7, GHSR | GHSR 3/4885ACE 1507/4885CTSC 492/4885 |
| US-20200261541-A1 | METHODS OF TREATING MILD BRAIN INJURY | FABP7, PYGB, ATP6V1B2 | GHSR 47/4885ACE 2327/4885CTSC 834/4885 |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | GHSR 1894/4885ACE 1799/4885CTSC 331/4885 |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | GHSR 1832/4885ACE 1033/4885CTSC 383/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | GHSR 1894/4885ACE 1799/4885CTSC 331/4885 |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | ATP6V1B2, GHSR, CRH | GHSR 2/4885ACE 1963/4885CTSC 457/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | GHSR 1457/4885ACE 1959/4885CTSC 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.